UK-based Motif Bio's skin disorder drug, iclaprim, has been denied approval by the US Food & Drug Administration (FDA) it was reported on Friday.
The product is intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
In the complete response letter, the US FDA stated that it cannot approve the company's New Drug Application (NDA) for the product in its present form. The regulator indicated to the company that additional data was required in the NDA to further evaluate the risk for liver toxicity prior to the drug's approval. The company stated that it will seek a meeting with the FDA as early as possible to explore potential options to address the shortcomings.
Iclaprim's NDA filed with the FDA included data from the REVIVE-1 and REVIVE-2 phase 3 trials in patients with ABSSSI. The product is a gram-positive investigational antibiotic. Its approval for the ABSSSI indication would make it eligible for 10 years of US market exclusivity.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study